Sera Prognostics, INC.: management transactions · United States · SEC (Form 4)

About Sera Prognostics, INC.

Sera Prognostics, Inc. is a U.S.-based medical diagnostics company listed on the NASDAQ exchange in the United States. Incorporated in Delaware on January 17, 2008, the company is headquartered in Salt Lake City, Utah, where it also operates a CLIA-certified laboratory. Sera’s business model sits at the intersection of proteomics, bioinformatics, and clinical evidence, with a clear focus on women’s health and maternal-neonatal risk prediction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001534969/000153496926000009/sera-20251231.htm?utm_source=openai)) The company’s flagship asset is the PreTRM blood test, designed to estimate the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, typically drawn around weeks 18 to 20 of gestation. More broadly, Sera develops and commercializes blood-based biomarker tests and predictive analytics products and services intended to provide actionable information to physicians, pregnant women, and healthcare payers. Management has consistently framed the company’s ambition as becoming a global leader in high-value women’s health diagnostics, with a dual emphasis on better clinical outcomes and improved healthcare economics. ([sera.com](https://www.sera.com/?utm_source=openai)) From a competitive standpoint, Sera operates in a specialized segment of reproductive and maternal health diagnostics where clinical validation, reimbursement access, and physician adoption are critical. Rather than competing as a broad diagnostics conglomerate, Sera’s differentiation is centered on a focused scientific platform and a product-led commercialization strategy. Over time, the company has invested in clinical studies, commercial infrastructure, and payer engagement to support adoption of PreTRM and related test-and-treat workflows. ([sera.com](https://www.sera.com/pregnancy-related-concerns/newsroom/sera-prognostics-completes-100-million-series-e-financing/?utm_source=openai)) Recent developments suggest that Sera is moving further from a clinical-stage profile toward a commercial organization. In 2026, the company said it had completed a comprehensive business review and was redirecting investment away from research-heavy activities toward reimbursement-driven commercialization, payer engagement, market access, and clinical adoption. Management also highlighted a longer cash runway and continued operational right-sizing. Separately, Sera has continued to publicize clinical evidence supporting PreTRM, including results from the PRIME and AVERT programs, which are intended to strengthen the case for early screening followed by targeted interventions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000025/sera-20260331.htm?utm_source=openai)) For investors, Sera should be viewed as a niche U.S. healthcare diagnostics company with an attractive clinical narrative, but one that still depends on successful reimbursement expansion, physician uptake, and sustained commercialization execution. Its positioning is distinct from a traditional biotech or large-cap diagnostics peer: the core value proposition is not therapeutic R&D, but a data-driven screening platform aimed at a large, under-addressed obstetric risk category. ([sera.com](https://www.sera.com/?utm_source=openai))